Just sitting here musing while reading through the q10 and wondering about alternate sources of funding. Came up with the following off the top of my head:

• If the US/Can market is 30mil potential customers, would it be an idea to ask each one for a loan/donation of say $10 for two years and in turn give them a $50 discount on their first order in late 2014/early 2015?
• Sell a coupon through something like groupon for say 15% off a years supply ($300 off) of "Inhaled, Fast Acting Insulin" redemable in 2015 for say $100 but to only 2M possible customers?
• Presell 650k annual dosages (current production capacity until build out at Danbury) to medical insurance coys for a 15% discount on future orders.
• Try the Bond Offering again but to the Med Insurance Industry, in particular to a small subset of insurers (ie exclusive) who have enough diabetic clients to cover the Danbury output. Remembering that there are a lot more medical exp involved with diabetic health management, than just he insulin, think I read a number closer to 6-8 thousand on average. Insurance companies are investment firms and offing them a chance at say 3-4% coupon rate and a 10-20% reduction on future diabetic (insulin+++) expenses...
• disclose the Middle East $200M mystery client (Israel???) and let their domestic client base put the squeeze on whatever govenment regulators are required
• Obvious Mr Mann - new 300M line of credit

Any Others? Remember be creative.

OOG

(sorry can't git the speel sheck ta wurk ;-)